← back to search

Adrian Gottschlich

German Cancer Research Center · DE
Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
h-index
17
citations
1,171
works
68
NIH funding
primary concept
email

Recent publications

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours
Nature Biomedical Engineering 2026cited by 2position: middledoi
Gut Microbiota Modulation through <i>Akkermansia</i> spp <i>.</i> Supplementation Increases CAR T-cell Potency
Cancer Discovery 2025cited by 19position: middledoi
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
Blood 2025cited by 9position: firstdoi
FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion
Blood Advances 2025cited by 1position: middledoi
Neuroinflammation detected by TSPO-PET precedes dopaminergic neuronal loss in mnt following BCMA-directed CAR-T therapy: Longitudinal multimodal neuroimaging and biomarker insights
Blood 2025cited by 0position: middledoi
Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies
Biological Chemistry 2024cited by 18position: middledoi
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma
Cancer Immunology Immunotherapy 2024cited by 4position: middledoi
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
Nature Biotechnology 2023cited by 108position: firstdoi
Programmable multispecific DNA-origami-based T-cell engagers
Nature Nanotechnology 2023cited by 99position: middledoi
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis
Immunity 2023cited by 81position: middledoi
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
Journal of Clinical Investigation 2022cited by 83position: middledoi
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function
British Journal of Cancer 2022cited by 40position: middledoi
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Nature Biomedical Engineering 2021cited by 172position: middledoi
P06.07 CXCR6 expression enhances accumulation of anti-mesothelin CAR T cells at the tumor site and their therapeutic efficacy in pancreatic cancer xenografts
2020cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sebastian Kobold · German Center for Infection Research6 papers (2020–2025)Stefan Endres · LMU Klinikum3 papers (2020–2024)Sebastian Theurich · Gene Therapy Laboratory3 papers (2024–2025)Ruth Grünmeier · Ludwig-Maximilians-Universität München3 papers (2022–2024)Florian Märkl · Ludwig-Maximilians-Universität München3 papers (2022–2025)Bruno L. Cadilha · University Hospital Regensburg2 papers (2020–2022)Kai Rejeski · Cornell University2 papers (2024–2025)Janina Dörr · Ludwig-Maximilians-Universität München2 papers (2022–2024)Christina Angeliki Tsiverioti · Ludwig-Maximilians-Universität München2 papers (2023–2024)Lina Majed · Ludwig-Maximilians-Universität München2 papers (2022–2024)Marion Subklewe · München Klinik2 papers (2024–2025)Mohamed-Reda Benmebarek · Center for Cancer Research2 papers (2020–2022)Sophia Stock · German Cancer Research Center2 papers (2022–2024)Nora Philipp · LMU Klinikum1 papers (2025–2025)Manouk Feinendegen · Ludwig-Maximilians-Universität München1 papers (2022–2022)Christine Hörth · Ludwig-Maximilians-Universität München1 papers (2020–2020)Philipp Metzger · The University of Western Australia1 papers (2020–2020)Veit Bücklein · Cancer Research Center1 papers (2025–2025)Nathalie L. Albert · Inserm1 papers (2025–2025)Matthias Kroiß · Siemens (Germany)1 papers (2024–2024)